Picture loading failed.

Anti-STAB1 therapeutic antibody (Pre-made Bexmarilimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Faron's wholly-owned novel precision cancer immunotherapy drug candidate, bexmarilimab, targets the Clever-1 receptor, known to be expressed on immunosuppressive macrophages in the tumour microenvironment and circulating in soluble form, and which is capable of directly inhibiting T-cell activation.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-066-1mg 1mg 3090
GMP-Bios-ab-066-10mg 10mg 21890
GMP-Bios-ab-066-100mg 100mg 148000
GMP-Bios-ab-066-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-STAB1 therapeutic antibody (Pre-made Bexmarilimab biosimilar,Whole mAb)
INN Name Bexmarilimab
TargetSTAB1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesFaron Pharmaceuticals
Conditions Approvedna
Conditions ActiveSolid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis
Conditions Discontinuedna
Development Techna